Type I IFN immunoprofiling in COVID-19 patients
Sophie Trouillet‐Assant, Sébastien Viel, Alexandre Gaymard, Sylvie Pons, Jean‐Christophe Richard, Magali Perret, Marine Villard, Karen Brengel‐Pesce, Bruno Lina, Mehdi Mezidi, Laurent Bitker, Alexandre Bélot, William Mouton, Guy Oriol, Christelle Compagnon, Laurence Generenaz, Valérie Cheynet, Florence Ader, Agathe Becker, Nicholas Benech, Pierre Chauvelot, Christian Chidiac, Anne Conrad, Tristan Ferry, Patrick Miailhes, Thomas Perpoint, Marielle Perry, Cécile Pouderoux, Sandrine Roux, Claire Triffault-Fillit, Florent Valour, Yonis Hodane, Louis Chauvelot, Paul Chabert, Judith Provoost, Guillaume David, Laure Folliet, Pierre Lecam, Geneviève Billaud, Maude Bouscambert, Vanessa Escuret, Émilie Frobert, Antonin Bal, Grégory Destras, Laurence Josset, Florence Morfin, Clément Munier, Martine Valette, Fabienne Venet, Lorna Garnier, Rémi Pescarmona, Christine Lombard, Thierry Walzer
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes coronavirus disease 2019 (COVID-19), is characterized by a wide spectrum of disease encompassing asymptomatic carriage, mild to severe upper respiratory tract illness that can evolve into respiratory failure, or rapidly progressing severe viral pneumonia with acute respiratory distress syndrome. Disease severity depends on viral strain, and host risk factors have been identified such as age and male sex. In addition, an excessive immune response has been identified in patients showing a cytokine storm associated with acute respiratory distress syndrome.